Acanthosis Nigricans in Fatty Liver: Underlying Cause
Acanthosis nigricans in a patient with fatty liver is caused by insulin resistance, which is the common pathophysiologic link between both conditions. 1, 2
Pathophysiologic Mechanism
The connection between acanthosis nigricans (AN) and fatty liver disease operates through insulin resistance as the central driver:
Insulin resistance leads to compensatory hyperinsulinemia, which stimulates insulin-like growth factor (IGF) receptors in keratinocytes and dermal fibroblasts, causing the characteristic hyperpigmented, velvety skin thickening of AN 1, 2
The same insulin resistance drives hepatic steatosis through increased hepatic de novo lipogenesis, impaired fatty acid oxidation, and increased delivery of free fatty acids to the liver 3
Nonalcoholic fatty liver disease (NAFLD) is directly related to insulin resistance and metabolic syndrome, with prevalence reaching 70% in obesity and 90% in diabetes mellitus 3
Clinical Evidence Supporting This Link
Recent research strongly validates AN as a clinical marker for metabolic dysfunction-associated steatotic liver disease:
AN independently predicts hepatic steatosis and fibrosis in patients with type 2 diabetes, with adjusted odds ratios of 2.47 (95% CI: 1.50-4.06) for hepatic fibrosis 4
AN predicts higher steatosis grades: multivariate analysis shows AN predicts S2 steatosis (OR = 6.58) and S3 steatosis (OR = 2.36) 5
Even in normal-weight individuals, the presence of AN with fatty liver indicates significant insulin resistance and ectopic fat deposition 6
Metabolic Syndrome Connection
Both conditions are manifestations of the broader metabolic syndrome constellation 3:
- Central obesity
- Dyslipidemia (elevated triglycerides, low HDL)
- Hypertension
- Impaired glucose metabolism or type 2 diabetes
- Insulin resistance (the unifying feature)
Important Clinical Caveats
Rare alternative causes must be excluded 1, 2:
- Genetic defects in insulin action: Mutations in the insulin receptor gene can cause severe insulin resistance with AN (formerly called "type A insulin resistance syndrome")
- Malignancy-associated AN: Though rare, AN can be paraneoplastic, including cholangiocarcinoma 7
- Medications: Certain drugs causing insulin resistance
- Endocrinopathies: Acromegaly, Cushing's syndrome, which cause both insulin resistance and can lead to fatty liver
Practical Clinical Application
AN serves as a visible, cost-effective screening tool for identifying patients at high risk for NAFLD and metabolic complications 5, 8:
- Check for AN in the neck, axillae, elbows, and knuckles during physical examination
- Presence of AN, particularly on knuckles, has OR 2.09 for liver steatosis 5
- When AN is present with fatty liver, aggressively screen for and manage metabolic comorbidities including diabetes, dyslipidemia, and hypertension 9, 10
The presence of both AN and fatty liver should prompt comprehensive metabolic evaluation and intensive lifestyle intervention targeting the underlying insulin resistance through weight loss (7-10% body weight), dietary modification (Mediterranean diet pattern), and regular physical activity (150-300 minutes weekly of moderate-intensity exercise) 11, 12, 13, 10.